Illegal Emissions Force Sanofi Production Stoppage
Executive Summary
Sanofi is working on technical improvements after its Mourenx site in southwest France was found to be emitting illegally high levels of solvents. Production at the site is on hold.
You may also be interested in...
UK Bans Valproate Use Without Pregnancy Prevention Program; First In EU To Do So?
Following the endorsement of EU-wide restrictions on the safe use of anti-epilepsy drug valproate, the UK appears to be the first member state to put in place a pregnancy prevention program to reduce the number of pregnancies exposed to valproate medicines to an absolute minimum and make sure all women and girls of childbearing potential are aware of the risks.
EMA Calls For Visual Warnings Among Measures To Restrict Valproate Use
The European Medicines Agency has recommended that EU member states should introduce further restrictions on the use of valproate-containing medicines to avoid the drug's exposure in pregnancy.
EMA Urged To Do Better On Valproate Risk Reduction In Pregnant Women
There were passionate testimonies from patients affected by Sanofi’s anti-epileptic drug valproate at the European Medicines Agency's first public hearing on medicines safety. There was almost full agreement among those who testified that existing risk reduction measures are not working.